The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers

Limited data exist on the real‐world costs of applying whole‐genome analysis (WGA) in a clinical setting. We estimated the costs of applying WGA to guide treatments for patients with advanced cancers and characterized how costs evolve over time.

[1]  Chris Chatfield,et al.  Introduction to Statistical Time Series. , 1976 .

[2]  J. Batley,et al.  Genome sequence data: management, storage, and visualization. , 2009, BioTechniques.

[3]  J. Veltman,et al.  The diagnostic pathway in complex paediatric neurology: a cost analysis. , 2015, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[4]  J. Barretina,et al.  Genomic medicine frontier in human solid tumors: prospects and challenges. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  klaguia,et al.  Reflections on the Cost of ‘Low-Cost’ Whole Genome Sequencing: Framing the Health Policy Debate , 2013 .

[6]  Shivang Doshi,et al.  Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis , 2016, The Journal of molecular diagnostics : JMD.

[7]  Tx Station.  Stata Statistical Software: Release 7. , 2001 .

[8]  Raymond K. Auerbach,et al.  The real cost of sequencing: higher than you think! , 2011, Genome Biology.

[9]  Lars Lundell,et al.  Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia , 2010, Genome Medicine.

[10]  R. Eils,et al.  Genome sequencing: a systematic review of health economic evidence , 2013, Health Economics Review.

[11]  M. Schatz,et al.  Big Data: Astronomical or Genomical? , 2015, PLoS biology.

[12]  M. Plöthner,et al.  Cost analysis of whole genome sequencing in German clinical practice , 2017, The European Journal of Health Economics.

[13]  E. Mardis.  The $1,000 genome, the $100,000 analysis? , 2010, Genome Medicine.

[14]  Daniele Merico,et al.  A microcosting and cost–consequence analysis of clinical genomic testing strategies in autism spectrum disorder , 2017, Genetics in Medicine.

[15]  H. B. Mann,et al.  On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other , 1947 .

[16]  Dan M. Roden,et al.  Implementing genomic medicine in the clinic: the future is here , 2013, Genetics in Medicine.

[17]  Delivering clinical whole genome analysis Clinical whole genome analysis : delivering the right diagnosis , 2022 .

[18]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[19]  L. Aaltonen,et al.  Diagnostic Cancer Genome Sequencing and the Contribution of Germline Variants , 2013, Science.

[20]  R. Service.  The Race for the $1000 Genome , 2006, Science.

[21]  A. Tretyn,et al.  Sequencing technologies and genome sequencing , 2011, Journal of Applied Genetics.

[22]  Colin C Pritchard,et al.  Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Chow.  Tests of equality between sets of coefficients in two linear regressions (econometrics voi 28 , 1960 .

[24]  Yuan Xue,et al.  Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing , 2014, Genetics in Medicine.

[25]  W. V. van Harten,et al.  Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis , 2016, Ecancermedicalscience.

[26]  S. Thompson,et al.  Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. , 2000, Statistics in medicine.

[27]  Anke M Hövels,et al.  Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability , 2016, Genetics in Medicine.

[28]  J. Stock,et al.  Efficient Tests for an Autoregressive Unit Root , 1992 .

[29]  Pascal Borry,et al.  Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate , 2013, PLoS biology.

[30]  Max Wintermark,et al.  Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. , 2015, Neuro-oncology.

[31]  Gil McVean,et al.  The 100,000 Genomes Project Protocol , 2017 .

[32]  Steven J. M. Jones,et al.  Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers , 2015, Cold Spring Harbor molecular case studies.

[33]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[34]  Lee Murray,et al.  The 100,000 Genomes Project , 2015 .

[35]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[36]  D. Scott,et al.  A time-and-motion approach to micro-costing of high-throughput genomic assays. , 2016, Current oncology.